Kornimate/medical-research-clean huggingface dataset:
non-contact sleep apnea identification in neurological rehabilitation

Conditions: Sleep Apnea; Stroke

Summary: to improve the quality of medical care in the group of poststroke patients, we are planning to examine neurological patients in a rehabilitation clinic simultaneously with a non-contact method (sleepiz one) and a standard diagnostic polygraphy measurement. this easy and comfortable pre-screening (sleepiz one) should reduce the barrier for ward physicians to request a sleep study. the method could help to overcome the bottleneck of resource-intense procedures. it is simple to carry out and does not disturb the sleep of the patients. the scoring is done according to the aasm manual version 2.6. patients with a confirmed diagnosis will be informed about therapy options by a sleep physician and receive a recommendation for further therapy in the discharge letter from the rehabilitation clinic. the goal of the study is then to evaluate if a non-contact method, the sleepiz one, presents an opportunity for a fast and easy pre-screening during rehabilitation. therefore, the precision of binary classification of subjects based on their sleep apnea severity (ahi \>= 15) made by sleepiz one will be compared to pg data manually scored by expert sleep scorers.


Eligibility criteria:
inclusion criteria: * age \>18years * ability and consent to undergo electrophysiological routine assessment * informed consent as documented by signature * in-patients of rehaclinic bad zurzach exclusion criteria: * previous enrolment into the current study, * enrolment of the investigator, his/her family members, employees and other dependent persons * cardiac pacemaker or another implanted electrical device * women who are pregnant or breastfeeding * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, delirium etc. of the participant

Keywords: stroke sleep apnea contactless screening
myocardial involvement of severe acute respiratory syndrome-cov-2 (covid19) infected patients

Conditions: Cardiomyopathies

Summary: the effects of severe acute respiratory syndrome sars-cov-2 (covid-19) on the myocardium and their role in the clinical course of infected patients are still unknown. epidemiological studies report biological myocardial involvement in 10 to 25% of cases. the objective of this study is to cardiac phenotype using comprehensive cardiac imaging tools of patients infected with covid 19 in order to explore the functional impact of the infection on the myocardium.

a large population of covid 19 infected patients of different ages and severity levels will be explored by transthoracic echocardiography with measurement of myocardial functional parameters such as ejection fraction, longitudinal strain and relaxation parameters and will be compared to an uninfected population paired for age and sex. patients with biological myocardial involvement will be followed to determine the evolution of their myocardial functional parameters during the course of the infection.

Eligibility criteria:
inclusion criteria: * major patients hospitalized for respiratory criteria for sars-cov-2 infection confirmed by rt-pcr exclusion criteria: * underage patients. patients refusing to participate in research. patients with a history of heart disease.

Keywords: left ventricular systolic function left ventricular diastolic function global longitudinal strain sars-cov-2 covid-19
efficiency and safety of association arbutin, triamcinolone and tretinoin in treatment of melasma

Conditions: Melasma

Summary: the objective of this study is evaluating the clinical activity of the association (tretinoin + arbutin + triamcinolone) in the treatment of epidermal melasma.

the melasma is a common hipermelanosis, acquired, symmetrical, with irregular occurring in areas such as photo-exposed face, forehead and temples, can affect the eyelids and tion. the facial regions most affected are: zigomatic (82.4%), parotid (64.7%), front (64.7%), mandible (35.3%) and nasal (35.3%). the injuries of melasma is variable increase of epidermal melanin and inflammatory infiltrate of mild to moderate intensity. treatment with compounds such as hydroquinone and derivatives, tretinoin, corticosteroids moderate or combination of them all have shown good results, diminishing the training, reducing the stability and promoting the destruction of melanocytes. the primary objective of this study is evaluating the clinical activity of the association (tretinoin + arbutin + triamcinolone) manufactured by glenmark laboratory, and as the comparator drug product triluma ® (hydroquinone + fluocinolone + tretinoin), in the treatment of epidermal melasma through parameters of clinical course of the disease (improves) and its security. patients who are included in the study will be randomly and automatically receive one of the treatments (new association or triluma ®), which should use for 12 weeks. the products should be applied in the regions affected once a day, during night. the evaluation of clinical improvement, as well as security, will be held on periodic visits, as described below, which will be held the record and supply of medicines to patients. in each visit, beyond the clinical examination of photographs and large, it filled the area and severity scale (melasma area and severity index - masi), which quantifies the melasma and will be the main tool of control of clinical improvement. at the end of the study, data will be compared, showing no inferiority or inferiority of clinical drug testing in relation to the comparator.

Eligibility criteria:
inclusion criteria: * women adults aged more than 18 years; * patients suffering from melasma epidermal the face of mild and moderate; * patients who have not done any treatment for melasma in the 3 months preceding the study; * patients with good mental and physical health; * patients who agree with the purposes of the study and sign the tcle. exclusion criteria: * patients with skin diseases other than melasma, which interfere in clinical evaluation as hemangiomas and queloides; * patients with melasma skin or mixed; * patients with sensitivity to agents hipopigmentantes; * patients with sensitivity to fotoprotetores; * patients who are pregnant or breastfeeding; * patients who, at the discretion doctor, are not able to participate in the study; * patients who have carried out any treatment for melasma in the 3 months preceding the study * patients who do not agree with the terms described in the statement of informed consent
glasgow natural history study of covered coronary interventions

Conditions: Coronary Artery Perforation; Coronary Stent Occlusion; Stent Thrombosis

Summary: covered stents (cs) are a potentially lifesaving treatment for grade iii coronary perforation but delivery can be challenging, and the long-term durability and safety including risk of acute stent thrombosis are unknown. the gnocci study aims to evaluate long term outcomes after coronary perforation including patients treated with covered stents.

covered stents (cs) are a potentially lifesaving treatment for grade iii coronary perforation but delivery can be challenging, and the long-term durability and safety including risk of acute stent thrombosis are unknown. using an electronic data base, details of all coronary perforations are identified and anonymised patient and procedural details are recorded.procedural major adverse cardiac events (pmace) are defined as a composite of death, myocardial infarction, stroke, target vessel revascularization or cardiac surgery within 24 hours of the index procedure. two independent cardiologists adjudicate outcomes and differences in opinion are resolved by consensus with a third cardiologist. the overall gnocci study aims are: 1. evaluate procedural and long term outcomes after coronary perforation 2. long term safety and clinical events in patients treated with covered stents.

Eligibility criteria:
inclusion criteria: * any coronary artery perforation during percutaneous coronary intervention exclusion criteria: * nil

Keywords: coronary artery perforation covered coronary stent calcific coronary disease
complications of ethanol-amine oleate intralesional sclerotherapy

Conditions: Venous Malformation

Summary: the aim of this study is to clarify complications of ethanolamine oleate intralesional injections of maxillofacial venous formations in pediatric patients

maxillofacial venous malformations cause many functional and esthetic complications in children, intralesional sclerotherapy is the best choice of treatment; and ethanol-amine oleate has been the most commonly used sclerosing agent. the aim of this study is to clarify complications of ethanolamine oleate intralesional injections of maxillofacial venous formations

Eligibility criteria:
inclusion criteria: maxillofacial venous malformation - exclusion criteria: 1. patients with lung, liver, or kidney diseases 2. patients with klippel-trenaunay syndrome 3. patients mental or physical disabilities

Keywords: maxillofacial pediatric venous malformations ethanol-amine oleate
impact of environmental exposures on tumor risk in subjects at risk of hereditary sdhx paraganglioma

Conditions: Genetic Predisposition; SDH Gene Mutation; Environmental Exposure

Summary: the main objective of the pilot phase of pglexpo will be to assess the faisability and to precise methodology of a case-control study designed for testing the impact of environmental and professional exposures on the tumoral risk in sdhx-mutation carriers

the main objective of the pilot phase of pglexpo will be to assess the faisability and to precise methodology of a case-control study designed for testing the impact of environmental and professional exposures on the tumoral risk in sdhx-mutation carriers. patients will be selected from subjects with a mutation in one of the sdhx genes. the cases will have developed a tumor, while the controls will be tumor-free. controls will be matched to the cases according to sex, age and type of gene affected. past exposures will be sought through a telephone questionnaire.

Eligibility criteria:
inclusion criteria: 1. cases: sdhx mutation carriers diagnosed for a sdhx-related tumor 2. controls: sdhx mutation carriers with no sdhx-related tumor exclusion criteria: incapacity to exercise free and informed consent for the study
a study on the safety and effectiveness of l-756423 plus indinavir in hiv-positive patients who have previously taken indinavir

Conditions: HIV Infections

Summary: the purpose of this study is to see if l-756423, an anti-hiv drug, is safe to give with indinavir and if it works well at lowering the level of hiv in the blood (viral load).

all patients receive l-756423 plus indinavir plus two licensed nucleoside reverse transcriptase inhibitors (nrtis), at least one to which the patient is naive. patients remain on the drug regimen for 12 weeks (with possible extension to 16 weeks). patients are evaluated with physical examinations and laboratory tests for blood and urine at weeks 1, 2, 4, 6, 8, and 12 and two weeks post study. plasma viral rna is measured at weeks 1, 2, 4, 6, 8, and 12. cd4 cell counts are measured at weeks 2,4,8, and 12.

Eligibility criteria:
inclusion criteria you may be eligible for this study if you: * are hiv-positive. * are at least 18 years old. * have a viral load of at least 1,000 copies/ml. * have a cd4 cell count of at least 100 cells/mm3. * have experienced treatment failure (your viral load increased significantly) within 24 weeks of study entry while taking indinavir. exclusion criteria you will not be eligible for this study if you: * are taking nonnucleoside reverse transcriptase inhibitors (nnrtis).

Keywords: drug therapy, combination hiv protease inhibitors indinavir reverse transcriptase inhibitors anti-hiv agents viral load
exercise intervention on frailty after kidney transplantation

Conditions: Kidney Transplant

Summary: researchers are trying to determine if exercise will improve health and strength in kidney transplant patients.


Eligibility criteria:
inclusion criteria: * patients age ≥ 18 years who have received a kt and have a functioning allograft exclusion criteria: * neuropsychiatric condition causing patient to be unable to provide consent * recipient of a combined organ transplant
examining the impact of using two dialysers in parallel on dialysis adequacy in hemodialysis patients

Conditions: End Stage Renal Disease

Summary: the purpose of this study is to investigate the effectiveness of using two dialysers to lower the blood mineral levels in people receiving hemodialysis as compared to using one dialyser (usual treatment).

higher levels of serum phosphate are independently associated with an increased risk of death in hemodialysis patients. therefore, there has been considerable interest in controlling serum phosphate while minimizing oral calcium load. while most attention has focused on the use of non-calcium containing phosphate binders such as sevelamer and lanthanum, modifying conventional dialysis regimens to improve phosphate clearance is an alternative approach that remains relatively unstudied. a secondary analysis of a previous randomized cross-over study from our group found that the use of two dialysers in parallel resulted in a reduction in pre-dialysis serum phosphate levels. as this study was small, and the mechanisms resulting in the reduction in phosphate levels were unclear, further study is warranted. the investigators will conduct a randomized cross-over study comparing the impact of dialyzing using two dialysers in parallel with a single dialyser in hyperphosphatemic hemodialysis patients. there will be a total of 34 participants from alberta,canada participating in this study. the length of study participation is 10 weeks.

Eligibility criteria:
inclusion criteria: * age \> 18 years * patients must be on a stable regimen of hemodialysis for ≥ 3 months ('stable' defined as not expected to require a change to the duration or frequency of treatments) * serum phosphate \> 1.6 mmol/l on last two consecutive lab tests at least 3 weeks apart (kdoqi guidelines recommend maintaining predialysis phosphate \< 1.8mmol/l - as such, phosphate lowering in this subgroup of patients is particularly relevant) * patients must be on stable doses of a phosphate binder with no changes in dose 1 month prior to study enrolment. * blood flow rate ≥ 350 ml/min through a well-functioning access (this will exclude patients receiving inadequate dialysis due to a temporary venous dialysis catheter and will ensure sufficient blood flow to permit dialysis using two dialysers in parallel.) exclusion criteria: * patients who have a scheduled renal transplant, change in dialysis modality, surgery or hospitalization or plan on moving away from the study site in the next three months. * patients with a projected life expectancy of less than 3 months. * patients with a contraindication to intra-dialytic anticoagulation. (some patients require a small increase in the amount of anticoagulation required to prevent dialyser clotting when using two dialysers in parallel). * patients who have missed \>8 dialysis treatments in the past 3 months. * patients with a dialysis regimen of \>3 runs per week. * failure to provide informed consent. * patients enrolled in another (interventional) trial

Keywords: hemodialysis adequacy phosphate clearance double dialyzer two dialyzers in parallel
the effect of the oligofructose supplementation on body weight in overweight and obese children

Conditions: Obesity

Summary: this study is designed to assess the effect of oligofructose administration for 12 weeks on body mass index (bmi) of overweight and obese children.

the prevalence of childhood overweight and obesity is reaching epidemic proportions. there have been no effective methods for preventing or treating obesity in childhood so far prompting interest in new interventions. one potential option for obesity prevention is the use of the prebiotic oligofructose. data from research on rodents shows that a high-fat diet enriched with oligofructose causes a decrease in energy intake, less weight gain and a lower level of triglycerides . a similar effect has been observed in healthy adults. available evidence suggests that the addition of oligofructose to the diets of overweight or obese adults may increase satiety and thus reduce energy intake. currently, there are no data on the effect of oligofructose in overweight and obese children.

Eligibility criteria:
inclusion criteria: * children aged 7 to 18 years * bmi \> 85 percentile * signed informed consent exclusion criteria: * overweight / obesity secondary to genetic syndromes and/or endocrine diseases

Keywords: obesity overweight satiety oligofructose prebiotic
a study to learn about flu and covid-19 vaccine responses in healthy people

Conditions: Influenza,Human; COVID-19

Summary: this study is to learn about flu and covid vaccines, either alone or when mixed together. healthy people aged 18 or older can join. participants will get one shot in each arm, either a flu or covid vaccine, alone or mixed. the study lasts about 6 months, and participants need to visit the research site at least 3 times.


Eligibility criteria:
inclusion criteria: * participants 18 years of age or older * healthy participants who are determined by medical history, physical examination (if clinically required), and clinical judgment of the investigator to be eligible for inclusion in the study. exclusion criteria: * vaccination with any investigational or licensed 2024-2025 season formulation influenza or covid-19 vaccine. * treated with antiviral therapies for influenza (eg, tamiflu) within 180 days prior to day 1 please refer to the study contact for further eligibility details.
inflammatory biomarkers for the diagnosis of opres

Conditions: Posterior Reversible Encephalopathy Syndrome; Inflammatory Biomarkers; Neutrophil-lymphocyte Ratio

Summary: the purpose of this study is to explore the inflammatory biomarkers for the diagnosis of obstetric posterior reversible encephalopathy syndrome.

the investigators retrospectively collected data (general information, clinical data, biochemical indicators, imaging features, and pregnancy outcome) from pregnant woman diagnosed with pres to explore the inflammatory biomarkers for the diagnosis of opres during 2012 to 2021.then, the investigators grouped all the patients into pres group (pe or e with pres) and not-pres group (pe or e without pres) according to the diagnostic criteria of pres. then, the investigators analysed the inflammatory biomarkers, such as neutrophil-lymphocyte ratio (nlr), platelet-lymphocyte ratio (plr), monocyte-lymphocyte ratio (mlr), and so on of two groups, and compared the difference of tow groups.

Eligibility criteria:
inclusion criteria: 1. pregnant women were diagnosed of pe or e. 2. all patients were examined the cranial imaging (mri or ct), and imaging findings meeting the diagnostic criteria of pres or normal. 3. all patients provided written informed consent. exclusion criteria: 1. patients combined with other neurological disorders 2. patients combined with mental illness
age-related variability of the efficacy and tolerability of alternative pituitary suppression regimens in art

Conditions: Infertility

Summary: age-related variability of the efficacy and tolerability of alternative pituitary suppression regimens in follicular stimulation for assisted reproduction purposes. a randomised, prospective, multi-centre clinical trial

pituitary suppression is strongly advised to be included within the follicular stimulation protocols to avoid the occurrence of a premature lh surge, which leads to cycle cancellation. however, whatever the drug and the schedule selected to achieve it, it is clear that pituitary suppression constitute a major perturbation of the endocrine milieu and that it has an impact on the outcome of the stimulation. indeed, the data in the literature support the idea that pituitary down-regulation by gnrh agonists according to the so-called long protocol, resulting in a deeper suppression, result in better clinical outcomes as compared to the short protocol, at least in women of younger reproductive age. conversely, it has been proposed that a less profound suppression (e.g. short protocol), that allows better background regulation from the pituitary, should be preferred in women of advanced reproductive age. however, the majority of the data currently supporting the decision makers in selecting their pituitary suppression strategies is based on studies focussed on standard, good prognosis patients whereas just a few studies have specifically addressed the special issue of the advanced reproductive age. inasmuch, very few data are available in pure (non resistant) advanced age patients and, however, no studies have compared in the same setting younger vs aged subjects with an adequate sample size. another intriguing aspect of the question is that the chronological age does not necessarily overlap with the reproductive age which, besides complicating the decisional process in the clinical practise, may also play as a confounding factor in the evaluation of the results from clinical trials. several studies have validated the role of the so-called follicle antral count (afc) and the anti-mullerian hormone (amh) circulating levels as having a predictive role in the evaluation of the actual reproductive age. in particular the latter, the amh, appears to be easier to standardise and to be used as the best reference in multicentre clinical studies focussed on the reproductive age. in summary, there is a clear lack of information on the performance of the different gnrh-agonist schedules in alternative chronological and reproductive age groups and the data from a large size prospective trial may generate valuable indications for the daily clinical practise.

Eligibility criteria:
inclusion criteria: * age 18 to 42 * first ivf attempt * bmi 18 to 25 * basal fsh less than 12 for subjects below the age of 35 or less than 15 for subjects aged more than 35 * informed consent exclusion criteria: * genital malformation * hypersensitivity to study drugs * major illnesses (to be specified) * pcos

Keywords: infertility ivf art